We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Non-Invasive Saliva Test for Early and Accurate Detection of Prostate Cancer Presented at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Illustration
Illustration

A new non-invasive test that uses saliva samples to accurately diagnose cases of prostate cancer was presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

The test developed by researchers at the Tehran University of Medical Sciences (Tehran, Iran) could allow clinicians to better distinguish early-stage prostate cancer from more benign prostate conditions.

A key challenge in cancer care is the diagnosis of prostate cancer, one of the most common cancers in men. Clinicians currently use invasive biopsies or tests for prostate-specific antigen levels to diagnose prostate cancer in the clinic. But prostate cancer can be hard to spot during the early stages and can be tricky to distinguish from benign prostatic hyperplasia (BPH), a benign enlargement of the prostate that can appear as men age.

In an effort to solve these issues, researchers have developed a new test for prostate cancer that uses saliva samples, which can be collected repeatedly and non-invasively. Their test distinguishes prostate cancer from BPH by testing saliva for eight different microRNAs that either support or suppress tumor growth. The researchers validated their test with saliva samples from 180 men between 45 and 50 years of age, 60 of whom had been diagnosed with prostate cancer using standard methods and 60 of whom had been diagnosed with BPH.

“The advantage of our study is the use of several microRNAs, which have been reported to be detectable in the blood much earlier than the progression of cancer, which makes for a better diagnosis, as well as the use of saliva as a non-invasive biological sample that causes little pain to patients,” said Dr. Jamal Amri of the Tehran University of Medical Sciences.

Related Links:
Tehran University of Medical Sciences 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette

Print article
ADLM

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.